Eisai announced an update on the regulatory review process of lecanemab by the European Medicines Agency (EMA). Additional details can be found in a news release available on Eisai’s website .

Eisai will host its annual information meeting which will include information on LEQEMBI ® (lecanemab-irmb). Materials and an audio webcast will also be posted on the Eisai website following its investor event on Friday, March 8 at 1:30 pm JST/Thursday, March 7 at 11:30 pm ET.

Eisai has announced an update on the regulatory review of lecanemab by the European Medicines Agency. Additional details can be found in a news release available on Eisai’s website (insert hyperlink).

JAMA Neurology published biomarker data from the placebo-controlled period (PCP) and long-term extension phase of the BIIB080 Phase 1b study of the antisense oligonucleotide (ASO) which targets tau pre-mRNA in early-stage Alzheimer's disease (AD). The publication follows the presentation of

Biogen confirms that today Reata Pharmaceuticals announced in a special meeting the stockholders of the company voted to approve the company’s previously announced acquisition by Biogen. For more information, read Reata’s Form 8-K disclosure.

Cambridge, Mass. – June 26, 2023 – Biogen Inc. (Nasdaq: BIIB) today held its Annual Meeting of shareholders. As previously announced, Caroline Dorsa has succeeded Stelios Papadopoulos as Chair of the Board of Directors at conclusion of the Annual Meeting.

As part of its ongoing Research & Development (R&D) prioritization initiative and resource allocation, Biogen announced plans to revise the clinical development program for BIIB122, a small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2), which is being developed in collaboration with

Biogen today filed a Form 8-K with the United States Securities and Exchange Commission, disclosing that "On May 3, 2023, the European Commission notified Biogen Inc. of its decision that the period of regulatory market protection for Tecfidera extends until February 2, 2025.”

Biogen has published its 2022 ESG Report, which supports Biogen’s business goals by sharing our corporate responsibility story, disclosing key environmental, social, and governance (ESG) data and providing updated progress against our targets and commitments. You can find a copy here.

Nature Medicine has published a manuscript detailing promising results from Biogen’s multiple ascending dose Phase 1b trial, which evaluated the safety, pharmacokinetics and target engagement of Biogen’s BIIB080 (MAPT ASO), an investigational antisense oligonucleotide targeting tau mRNA in